Novo Nordisk A/SNVONYSE
Loading
SG&A Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+10.2%
5Y CAGR+13.0%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+10.2%/yr
vs +11.1%/yr prior
5Y CAGR
+13.0%/yr
Consistent
Acceleration
-0.8pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.8x
Solid growth
Streak
8 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $67.87B | +0.7% |
| 2024 | $67.38B | +9.4% |
| 2023 | $61.60B | +21.5% |
| 2022 | $50.68B | +23.4% |
| 2021 | $41.06B | +11.3% |
| 2020 | $36.89B | +2.9% |
| 2019 | $35.83B | +7.6% |
| 2018 | $33.31B | +3.7% |
| 2017 | $32.12B | -0.7% |
| 2016 | $32.34B | - |